US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

35.86

+0.27000.76%

Post-market: 35.860.00000.00%19:30 EDT

Volume:174.97K

Turnover:6.28M

Market Cap:3.10B

PE:5.80

High:36.10

Open:35.58

Low:35.39

Close:35.59

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.87

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.45

PE(LYR):64.61

Loading ...

Overview Company News Filings

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Signing Day Sports sets BlockchAIn merger exchange ratio at 0.09 shares

Array Digital Infrastructure Inc. Announces Annual Shareholder Meeting

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

Zhongtai Securities: Draft Guidelines for Laboratory Test Pricing Issued, Offering Surcharge Potential for Innovative Assays and Listing AD Marker Tests

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

Press Release: Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

Press Release: ADENTRA Announces Annual and Fourth Quarter 2025 Results

Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million

Apogee Therapeutics: Strong Phase II AD Data and 2026 Readouts Underpin Buy Rating and Potential to Displace JAK-Based Regimens

Press Release: Longeveron Announces Private Placement of up to $30 Million

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Press Release: ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/AD/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":35.86,"timestamp":1787688000000,"preClose":35.59,"halted":0,"volume":174970,"hourTrading":{"tag":"盘后","latestPrice":35.86,"preClose":35.86,"latestTime":"19:30 EDT","volume":587,"amount":21049.82,"timestamp":1787700601509,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007586400674346614,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Not Yet Opened","change":0.27,"latestTime":"08-25 16:00:00 EDT","open":35.58,"high":36.1,"low":35.39,"amount":6279990.87055,"amplitude":0.019949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":35.59,"postHourTrading":{"tag":"盘后","latestPrice":35.86,"preClose":35.86,"latestTime":"19:30 EDT","volume":587,"amount":21049.82,"timestamp":1787700601509,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.872417,"impliedVol":0.2103,"impliedVolPercentile":0.136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.872417,"shares":86379877,"dividePrice":0,"high":36.1,"amplitude":0.019949,"preClose":35.59,"low":35.39,"week52Low":33.71,"pbRate":"2.45","psRate":"14.51","week52High":60.82,"institutionHeld":0.3358,"latestPrice":35.86,"eps":6.185934,"divideRate":0,"volume":174970,"delay":0,"ttmEps":6.185934,"open":35.58,"prevYearClose":53.62,"prevWeekClose":35.66,"prevMonthClose":34.84,"prevQuarterClose":36.26,"fiveDayClose":35.05,"twentyDayClose":35,"sixtyDayClose":50.86,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-08-24","current":5.797023,"percent":0.272374,"low":-273.92211,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"high":320.844562,"avg":59.893555,"sd":173.763323,"marketCap":3083841140},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-24","current":5.758764,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"marketCap":3083841140}],"updateTime":1787693235089},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620424058","title":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424058","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748800,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., March  17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid bet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257081/0/en/Acumen-Pharmaceuticals-Presents-Studies-on-Enhanced-Brain-Delivery-Biomarker-Research-and-Novel-Antibodies-at-Advances-in-Alzheimer-s-Treatment-at-International-Conference-on-Alzhe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4585","ABOS","BBB","BK4132","SPR","BK4588","AD","BK4187","BK4139","BK4539","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429768","title":"Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429768?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., March  17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257029/0/en/Cognition-Therapeutics-Presents-Evidence-of-Zervimesine-s-Impact-on-Neuropsychiatric-Symptoms-of-Dementia-with-Lewy-Bodies-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0240877869.USD","LU0240878834.USD","CGTX","BK4097","AD","LU0348723411.USD","LU0205193047.USD","BK4132","DLB","LU0205194284.USD","LU1169589451.USD","LU1169590202.USD","LU0345774631.USD","BK4023","LU0345774391.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620912425","title":"Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2620912425","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620912425?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:35","pubTimestamp":1773743720,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on ABOS stock, giving a Buy rating yesterday. Jason Zemansky ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-acumen-abos-ebd-enabled-alzheimers-pipeline-extended-runway-and-discounted-valuation-ahead-of-altitude-ad-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-acumen-abos-ebd-enabled-alzheimers-pipeline-extended-runway-and-discounted-valuation-ahead-of-altitude-ad-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BBT3K403.USD","LU1791807156.HKD","LU0106831901.USD","LU0640476718.USD","LU1363072403.SGD","BAC","IE00B7SZLL34.SGD","IE0034235188.USD","LU0203347892.USD","LU0980610538.SGD","LU0070302665.USD","ABOS","LU1035773651.USD","LU0211331839.USD","LU1201861249.SGD","LU1069347547.HKD","BK4504","AD","LU0170899867.USD","LU0052756011.USD","LU1883839398.USD","BK4588","LU2129689605.HKD","LU0648001328.SGD","LU0130517989.USD","LU0128525689.USD","IE0001KFT4U8.USD","LU0648000940.SGD","LU0310800965.SGD","LU0256863811.USD","LU0320765489.SGD","IE00BKVL7J92.USD","LU0971096721.USD","LU0477156797.USD","LU0098860793.USD","LU0149725797.USD","LU0306807586.USD","IE00BLSP4452.SGD","LU0256863902.USD","LU1880398554.USD","IE00BLSP4239.USD","LU0208291251.USD","BK4539","LU0320765646.SGD","BK4559","LU0787776722.HKD","LU2129689514.USD","LU1496350502.SGD","LU0130103400.USD","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619363454","title":"Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619363454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619363454?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:30","pubTimestamp":1773657000,"startTime":"0","endTime":"0","summary":"Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256089/0/en/Acumen-Pharmaceuticals-Announces-35-75-Million-Private-Placement-to-Advance-Potential-Best-in-Class-Molecules-from-Amyloid-Beta-Oligomer-Selective-Enhanced-Brain-Delivery-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CNS","BK4132","ABOS","AD","BBB","BK4139","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619148791","title":"Signing Day Sports sets BlockchAIn merger exchange ratio at 0.09 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148791","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148791?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:55","pubTimestamp":1773435305,"startTime":"0","endTime":"0","summary":"Signing Day Sports is set to combine with BlockchAIn Digital Infrastructure under a business combination agreement dated May 27, 2025 and amended on Nov. 10, 2025 and Dec. 21, 2025. The closing is anticipated on March 16, 2026, subject to final NYSE American listing approval for BlockchAIn common shares. Based on a $0.70 last reported sale price for Signing Day Sports shares on March 13, 2026, the final exchange ratio was set at 0.09334 BlockchAIn shares per Signing Day Sports share. Any fractional BlockchAIn share resulting from the exchange ratio is expected to be rounded up to 1 share for that fractional entitlement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Signing Day Sports Inc. published the original content used to generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL9KVkQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4608","BK4023","BK4132","SGN","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619461148","title":"Array Digital Infrastructure Inc. Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619461148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619461148?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:46","pubTimestamp":1773434808,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL4NnqMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","TDS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619993641","title":"Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993641?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"-- Phase 2 interim results suggest treatment with active immunotherapy. ACI-7104 may slow the progression of Parkinson's disease. -- NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants. of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's. disease in H1 2026, and full 24-month data from Part 1 of the Phase 2. funding to the end of Q3 2027 before any potential milestone payments. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting <ALPHA>-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson's disease  further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.\". Phase 2 VacSYn trial of our ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","PD","BK4104","BK4113","AD","LU1169589451.USD","CAPS","ACIU","TM","BK4555","R","BK4139","IND","LU1169590202.USD","BK4604","BK4232","BK4099","BK4132","BK4022","BK4585","ACI","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619162495","title":"CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162495","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619162495?lang=en_us&edition=fundamental","pubTime":"2026-03-13 16:25","pubTimestamp":1773390300,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, March  13, 2026 (GLOBE NEWSWIRE) -- On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limite","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/13/3255280/0/en/CMS-867-HK-8A8-SG-Ruxolitinib-Phosphate-Cream-Lumirix-Achieves-Initial-Prescriptions-in-Multiple-Regions-in-China-for-Patients-with-Vitiligo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCS","LU0553294199.USD","BK4081","LU1880398554.USD","EMA","BK4588","LU2346227817.USD","BK4132","BK4200","AD","LU0545039389.USD","LU0949170772.SGD","BK4208","LU1894683348.USD","LU1883839398.USD","LU0738911758.USD","LU2500361329.USD","BK4211","RF","LU0661504455.SGD","CMS","LU2637428348.USD","LU1003077747.HKD","LU1894683264.USD","BK4585","LU1880398471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172282830","title":"Zhongtai Securities: Draft Guidelines for Laboratory Test Pricing Issued, Offering Surcharge Potential for Innovative Assays and Listing AD Marker Tests","url":"https://stock-news.laohu8.com/highlight/detail?id=1172282830","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172282830?lang=en_us&edition=fundamental","pubTime":"2026-03-13 13:54","pubTimestamp":1773381284,"startTime":"0","endTime":"0","summary":"Zhongtai Securities has released a research report stating that the newly issued draft guidelines for laboratory test pricing primarily represent a standardization and restructuring of the price...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600918","BK0276","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618317361","title":"BioVie Announces Abstract Accepted for Presentation at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618317361","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618317361?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., March  12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254576/0/en/BioVie-Announces-Abstract-Accepted-for-Presentation-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","AD","BIVI","BK4132","PD","BK4023","BK4139","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131225","title":"Press Release: Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131225?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, March 12, 2026  -- Filana Therapeutics, Inc.  , a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system  disorders, such as Tuberous Sclerosis Complex -related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.\"At Filana Therapeutics, our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by the urgent need for new treatment options that can meaningfully improve patients' lives,\" said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. \"In partnership with our advisors, we are working diligently to address the FDA's requests and look forward to sharing a progress update in the coming months.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","IND","AD","LENZ","BK4132","BK4539","FLNA","BK4139","BK4007","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618813614","title":"Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618813614","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618813614?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313200,"startTime":"0","endTime":"0","summary":"Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254480/0/en/Gain-Therapeutics-Announces-Presentations-at-AD-PDTM-2026-and-Provides-U-S-FDA-Regulatory-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4585","LABU","BK4023","BK4119","BK4139","AD","LU1169589451.USD","GT","BK4132","PD","LU1169590202.USD","BK4588","GANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618361401","title":"CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618361401","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618361401?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313200,"startTime":"0","endTime":"0","summary":"Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, affectin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254471/0/en/CervoMed-Announces-Presentations-at-Upcoming-AD-PD-2026-Scientific-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4205","BK4132","AD","PD","LU0240877869.USD","BK4528","CRVO","BK4097","UK","LU0205194284.USD","LU0240878834.USD","BK4233","LU0345774391.USD","LU0348723411.USD","BK4139","DLB","LU1169590202.USD","LU1169589451.USD","LU0345774631.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974237","title":"Press Release: ADENTRA Announces Annual and Fourth Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974237","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974237?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:29","pubTimestamp":1773271740,"startTime":"0","endTime":"0","summary":"Earnings per share of U.S.$1.32 and Adjusted EBITDA of U.S.$43.7 Million. LANGLEY, BC, March 11, 2026 /CNW/ - ADENTRA Inc.  today announced financial results for the three and twelve months ended December 31, 2025. ADENTRA is one of North America's largest distributors of architectural building products to the residential, repair and remodel, and commercial construction markets. We currently operate a network of 81 facilities in the United States and Canada. All amounts are shown in United States dollars , unless otherwise noted.-- Generated full-year sales of $2.25 billion , an increase. of 3.0% compared to $2.18 billion  in the prior year. Q4. sales decreased to $517.5 million , from $530.8 million. -- Gross margin percentage remained strong and steady at 21.7% in 2025; Q4. 2025 gross margin percentage increased to 22.1%, from 21.7% in Q4 2024.-- Operating expenses increased by $7.6 million to $384.8 million, from. , from $0.34  per share in Q4 2024.Consolidated sales grew 3% year-ov","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618739449","title":"Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618739449","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618739449?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259500,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement was led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory development of laromestrocel, working capital and other general corporate purposes. B","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4150","R","BK4022","BK4232","AD","BK4575","BK4139","MSC","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618956288","title":"Apogee Therapeutics: Strong Phase II AD Data and 2026 Readouts Underpin Buy Rating and Potential to Displace JAK-Based Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956288","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618956288?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:45","pubTimestamp":1773150325,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on March 5. Tyler Van Buren has given his B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-strong-phase-ii-ad-data-and-2026-readouts-underpin-buy-rating-and-potential-to-displace-jak-based-regimens-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/apogee-therapeutics-strong-phase-ii-ad-data-and-2026-readouts-underpin-buy-rating-and-potential-to-displace-jak-based-regimens-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953902","title":"Press Release: Longeveron Announces Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953902?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:01","pubTimestamp":1773147660,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4232","BK4132","MSC","AD","R","LGVN","BK4022","BK4150","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618555289","title":"Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2618555289","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618555289?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:00","pubTimestamp":1773147600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  10, 2026  (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252908/0/en/Results-from-Phase-3-Study-of-Rademikibart-in-Moderate-to-Severe-Atopic-Dermatitis-to-be-Presented-in-the-Late-Breaking-Research-Session-at-the-2026-American-Academy-of-Dermatology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AFG","AD","BK4117","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937022","title":"Press Release: ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937022?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 10, 2026  -- ImageneBio, Inc.   today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update.-- The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe. atopic dermatitis  is ongoing at North American sites; the study. began enrolling in mid-2025 with topline data expected in 2027. A recent. blinded safety review showed a favorable emerging tolerability profile. -- The Company has submitted a protocol amendment intended to expand the. number and exposure range of dosing regimens being evaluated,characterize the role of loading doses, evaluate patient-friendly dosing. intervals, and understand the effect of short- and longer-term treatment. -- The Company welcomed Dr. Ben Porter-Brown, who brings deep inflammation. and medical dermatology experience including leading the development of. anti-OX40L investigational therapeutic amlitelimab through the end of. characterization of the non-depleting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMA","AD","SID","BK4006","BK4007","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618745986","title":"Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618745986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618745986?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":"- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3252283/36461/en/Voyager-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4590","BK4217","GLP","SMA","AD","BK4144","IND"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}